CTRI/2023/06/054459Not yet recruitingUnknown
ASSESSMENT OF EFFICACY OF DAPAGLIFLOZIN IN PATIENTS OF LIVER CIRRHOSIS WITH DIABETES MELLITUS AS COMPARED TO STANDARD MEDICAL TREATMENT
Pt BD Sharma Institute of Medical Science, Rohtak0 sites0 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Unknown
- Status
- Not yet recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •All Patients with liver cirrhosis having age 18years to 70years with Diabetes Mellitus requiring drug treatment. Patients who are willing to participate
Exclusion Criteria
- •Age <18years or >70years. Cerebrovascular disorder, any neurological disorder including dementia/Alzheimerâ??s etc.Pregnancy.Chronic kidney disease . Any malignancy excluding Hepatocellular Carcinoma .Patient who refused to give consent.
Investigators
Similar Trials
Recruiting
Phase 4
Dapagliflozin in Chronic Heart failure patientChronic Heart Failure.Chronic combined systolic (congestive) and diastolic (congestive) heart failureI50.42IRCT20230331057788N1ational University of Medical Sciences170
Completed
Not Applicable
A STUDY TO EVALUATE THE EFFECT OF DAPAGLIFLOZIN ON RENAL OUTCOMES AND CARDIOVASCULAR MORTALITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE-N19 Unspecified kidney failureUnspecified kidney failureN19PER-055-16ASTRAZENECA PERU S.A.,218
Recruiting
Not Applicable
Examination of the efficacy of dapagliflozin in patients with type 2 diabetesType 2 diabetesJPRN-UMIN000021954Tonami general hospital Department of diabetes mellitus and endocrinology200
Completed
Not Applicable
Patient Reported Outcome study of Dapagliflozin on glycemic control and treatment satisfaction in overweight patients with type 2 diabetes mellitusOverweight patients with type 2 diabetes mellitusJPRN-UMIN000016304Japan society for Patient Reported Outcome220
Not yet recruiting
Not Applicable
Dapagliflozin in Heart FailureCTRI/2022/11/047725Sanjay Kumar R